Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- Conditions
- Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic MyelodysplasiaMyeloid Leukemia, AcuteNonlymphoblastic Leukemia, Acute
- Interventions
- Biological: Individual Patient TCR-Transduced PBLDevice: TruSight Oncology (TSO) 500
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT06904066
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
- Conditions
- Gastrointestinal CarcinomaPancreatic CancerHepatocellular CancerCholangiocarcinomaDuodenal CancerColorectal CancerSmall Bowel CancerMetastatic Cancers
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT06690281
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
- Conditions
- Locally Advanced Cervical CarcinomaLocally Advanced Colorectal CarcinomaLocally Advanced Malignant Solid NeoplasmLocally Advanced MelanomaLocally Advanced Pancreatic Ductal AdenocarcinomaLocally Advanced Renal Cell CarcinomaMetastatic Cervical CarcinomaMetastatic Colorectal CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Melanoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Excisional BiopsyProcedure: Magnetic Resonance ImagingProcedure: Standard TreatmentBiological: Therapeutic Tumor Infiltrating Lymphocytes
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT06626256
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study
- Conditions
- Acute Coronary Syndromes
- Interventions
- Drug: Dextrose 5% in water
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-06-10
- Target Recruit Count
- 60
- Registration Number
- NCT06427694
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
- Conditions
- Non-Small Cell Lung CancerGastrointestinal CancerOvarian CancerMetastatic Solid CancersColorectal CancerBreast CancerGenitourinary Cancer
- Interventions
- Biological: KRAS TCR-Transduced PBL
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 210
- Registration Number
- NCT06253520
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
- Conditions
- Squamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-03-12
- Target Recruit Count
- 15
- Registration Number
- NCT06236425
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
- Conditions
- Melanoma Stage IVMelanomaMelanoma Stage III
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 10
- Registration Number
- NCT06204991
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T LymphocytesProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: EchocardiographyProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: MammogramProcedure: Multigated Acquisition ScanProcedure: Ultrasound Imaging
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 20
- Registration Number
- NCT05989828
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Low Dose IL2 Immunotherapy in AD
- Conditions
- Alzheimer Disease
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 8
- Registration Number
- NCT05821153
- Locations
- 🇺🇸
Alireza Faridar, Houston, Texas, United States
Aldesleukin with Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer with Peritoneal Metastasis
- Conditions
- Clinical Stage IV Gastric Cancer AJCC V8Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaMetastatic Gastric CarcinomaMetastatic Malignant Neoplasm in the Peritoneum
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Diagnostic LaparoscopyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 15
- Registration Number
- NCT05802056
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.